The Journal of dermatological treatment最新文献

Comparative efficacy of topical garlic extract and 20% podophyllin solution in the treatment of female genital warts: a triple-blind randomized clinical trial. 局部大蒜提取物与20%鬼臼碱溶液治疗女性生殖器疣的比较疗效：一项三盲随机临床试验。

IF 3.9

The Journal of dermatological treatment Pub Date : 2027-12-01 Epub Date: 2026-10-12 DOI: 10.1080/09546634.2026.2746272

Mohsen Naseri, Zahra Sarfallah, Mina Saadat, Fatemeh Masaebi, Maryam Damghanian

{"title":"Comparative efficacy of topical garlic extract and 20% podophyllin solution in the treatment of female genital warts: a triple-blind randomized clinical trial.","authors":"Mohsen Naseri, Zahra Sarfallah, Mina Saadat, Fatemeh Masaebi, Maryam Damghanian","doi":"10.1080/09546634.2026.2746272","DOIUrl":"10.1080/09546634.2026.2746272","url":null,"abstract":"Background: Genital warts caused by human papillomavirus are common sexually transmitted infections, with no single therapy providing consistent clearance. Garlic extract has antiviral and antiproliferative properties and may offer a low-cost treatment.Objective: To compare the efficacy and safety of topical 5% garlic extract with 20% podophyllin solution in women with genital warts.Methods: Seventy-four women were randomized to 5% garlic extract (n = 37) or 20% podophyllin (n = 37), applied weekly for four weeks. Wart size and count were assessed using marginal models (generalized estimating equations). The primary outcome was change in mean wart size and the secondary outcome was change in wart count.Results: Mean wart size decreased from 1.61 ± 0.81 to 0.60 ± 0.82 mm with garlic extract and from 2.96 ± 7.99 to 0.62 ± 0.73 mm with podophyllin. The between-group p-value at final assessment was 0.756; group × time interaction p values were 0.329 for wart size and 0.583 for count. Among 35 and 37 participants analyzed, complete response occurred in 18 (51.4%) and 19 (51.4%), respectively; complete or partial response occurred in 23 (65.7%) and 25 (67.6%). Itching and burning occurred in 8 (21.6%) garlic-treated participants each.Conclusion: Both treatments reduced wart size and count, with similar response rates. Four-week follow-up precluded assessment of durability and recurrence.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"38 1","pages":"2746272"},"PeriodicalIF":3.9,"publicationDate":"2027-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial. 依瓦马替尼在中度至重度特应性皮炎患者中的应用：一项3期临床试验的事后分析

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-29 DOI: 10.1080/09546634.2025.2596524

Chaoying Gu, Aijun Chen, Huibin Yin, Suwei Tang, Jinhua Xu

{"title":"Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial.","authors":"Chaoying Gu, Aijun Chen, Huibin Yin, Suwei Tang, Jinhua Xu","doi":"10.1080/09546634.2025.2596524","DOIUrl":"https://doi.org/10.1080/09546634.2025.2596524","url":null,"abstract":"Background: Ivarmacitinib (SHR0302) is a novel and highly selective Janus kinase 1 inhibitor for treating moderate to severe atopic dermatitis (AD).Objective: This study aimed to evaluate the impacts of patient characteristics on the efficacy and safety of Ivarmacitinib.Methods: This post-hoc analysis used data from a randomized, double-blind, placebo-controlled, multicenter phase 3 trial of Ivarmacitinib in patients with moderate to severe AD in which patients were randomized (1:1:1) to receive Ivarmacitinib 4 mg or 8 mg or placebo for 16 weeks. Subgroup analyses were conducted based on baseline characteristics.Results: At week 16, both Ivarmacitinib 4 or 8 mg showed better efficacy over placebo in achieving Eczema Area and Severity Index (EASI) 75, EASI 90, and Worst Itch Numeric Rating Scale (WI-NRS) score ≥4-point responses in most subgroups based on age, sex, body mass index, AD duration, Investigator's Global Assessment score, EASI score, WI-NRS score, body surface area involvement, history of comorbid allergies, or previous systemic therapies. The overall incidence of adverse events and most of the adverse events of special interest were similar between Ivarmacitinib and placebo across all subgroups.Conclusion: Ivarmacitinib demonstrated efficacy and good tolerability in treating moderate to severe AD with diverse patient characteristics.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2596524"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimated cost savings and formulary coverage barriers in biosimilar adoption. 生物仿制药采用的估计成本节约和处方覆盖障碍。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-13 DOI: 10.1080/09546634.2025.2610921

Alina S Feng, I-Chun Lin, Christopher G Youn, Wilson Liao

引用次数: 0

Oral propranolol treatment safety in infantile hemangiomas. 口服心得安治疗婴幼儿血管瘤的安全性。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-05-25 DOI: 10.1080/09546634.2026.2671601

Sami Alsuwaidan, Tala A Qadoumi, Reem Alsergani, Rana K Almazrou

{"title":"Oral propranolol treatment safety in infantile hemangiomas.","authors":"Sami Alsuwaidan, Tala A Qadoumi, Reem Alsergani, Rana K Almazrou","doi":"10.1080/09546634.2026.2671601","DOIUrl":"10.1080/09546634.2026.2671601","url":null,"abstract":"Introduction: Infantile hemangiomas are common and can be treated with propranolol. Cardiovascular side effects are a potential risk of propranolol treatment. We assessed real-world propranolol side effects to help guide safe use of propranolol for infantile hemangiomas.Materials and methods: This is a descriptive cross-sectional study using retrospectively collected data from patients' electronic medical records from 2015 to 2023, with a sample of 64 patients. Patients diagnosed with infantile hemangiomas, who received oral propranolol, were included in the study. Data regarding the clinical features of the hemangiomas, oral propranolol dosing regimen, treatment response, adverse effects, and rebound hemangioma rate was collected.Results: Seventy percent of the hemangiomas were less than 10 cm2 in size. Adverse effects were uncommon. The most common adverse effects were hyperkalemia, hypotension, and nightmares, which accounted for 23%, 9%, and 9% of patients, respectively. After treatment, 81% of the hemangiomas completely resolved, 8% demonstrated partial improvement, and 8% exhibited no improvement. The rate of rebound hemangiomas was 3%.Conclusion: The majority of patients with infantile hemangioma can be safely managed with oral propranolol in an outpatient setting.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2671601"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148019307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JAK inhibitor-associated acne: a mechanistic paradox with important clinical implications. JAK抑制剂相关性痤疮：具有重要临床意义的机制悖论。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-06-29 DOI: 10.1080/09546634.2026.2670082

Duorong Zeng, Zhimin Lin, Wen Yin, Xinna Zhao, Chenran Lyu, Chen Li, Junling Zhang

引用次数: 0

Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study. 轻中度牛皮癣患者系统治疗的医疗资源利用：一项英国单中心纵向回顾性队列研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-13 DOI: 10.1080/09546634.2026.2640305

Elizaveta Gribaleva, Erin Barker, Neil Hansell, Tejus Dasandi, Qin Neville, Angela Clifford, John Gregory, Laura Bojke, Joe W E Moss, Catherine H Smith, Jonathan Barker, Andrew E Pink

{"title":"Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study.","authors":"Elizaveta Gribaleva, Erin Barker, Neil Hansell, Tejus Dasandi, Qin Neville, Angela Clifford, John Gregory, Laura Bojke, Joe W E Moss, Catherine H Smith, Jonathan Barker, Andrew E Pink","doi":"10.1080/09546634.2026.2640305","DOIUrl":"10.1080/09546634.2026.2640305","url":null,"abstract":"Background: Healthcare resource utilization (HCRU) costs in those on conventional systemics for mild-moderate psoriasis are poorly described.Objectives: This study aimed to describe HRCU, disease severity and health-related quality of life in patients with mild-moderate psoriasis requiring systemic therapy.Methods: UK single-center retrospective longitudinal cohort study including adults with mild-moderate psoriasis (PASI < 10, no historical PASI ≥ 10, no prior biologics) on conventional systemic therapy with 3-year data capture from first PASI recording (2014-2019, pre-COVID). Patients discontinued due to reaching PASI ≥ 10, starting biologics or being lost to follow-up.Results: The median annual HCRU cost was £1923 (mean £3361), largely driven by visit costs. A total of 50.8% patients achieved a PASI ≤ 2 and 30.6% achieved PASI ≤ 2 and DLQI ≤ 5 during follow-up. The difference between the maximum and minimum PASI for a patient and follow-up time were statistically significant predictors of total costs (p < 0.05).Conclusion: Despite high healthcare costs, nearly half of the patients did not achieve clear/nearly clear skin. These data, in the context of reducing costs for biosimilars, may provide a basis to challenge care pathways and access criteria for 'high-cost' treatments.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2640305"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of disease control and perceived risk on atopic dermatitis treatment decisions. 疾病控制和感知风险对特应性皮炎治疗决策的影响。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-04-27 DOI: 10.1080/09546634.2026.2655503

Allison R Loiselle, Jessica K Johnson, Wendy Smith Begolka

{"title":"Influence of disease control and perceived risk on atopic dermatitis treatment decisions.","authors":"Allison R Loiselle, Jessica K Johnson, Wendy Smith Begolka","doi":"10.1080/09546634.2026.2655503","DOIUrl":"10.1080/09546634.2026.2655503","url":null,"abstract":"Objective: Patients with atopic dermatitis (AD) face an increasingly complex treatment landscape with prescription options that vary in efficacy, safety, and mode of administration. The aim of this study was to evaluate how real-world factors such as risk tolerance, side effect (SE) concerns, and disease control influence treatment decisions.Methods: A cross-sectional electronic survey (January-April 2025) of U.S. adults with self-reported AD and caregivers was conducted to assess how they weigh treatment benefits and risks. Negative binomial regression examined predictors of the number of SEs prioritized over rapid symptom relief when AD is at its worst.Results: Included respondents (796 adults, 113 caregivers) most frequently reported unknown long-term SEs (618; 68.0%), liver or kidney problems (610; 67.1%), and allergic reactions (538; 59.2%) as SEs of concern. Over one quarter (26.1%) prioritized avoidance of ≥5 SEs over rapid symptom relief. Caregivers prioritized 40% more SEs over rapid relief than adult patients (adj IRR, 1.40; 95% CI, 1.22-1.61). Higher willingness to take health-related risks was associated with prioritizing fewer SEs (adj IRR, 0.95; 95% CI, 0.93-0.96), but AD control status was not significantly associated with SE prioritization.Conclusion: These findings demonstrate that safety concerns strongly influence treatment decision-making in AD, underscoring the need for transparent, personalized discussions to support shared decision-making.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2655503"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment. dupilumab和upadacitinib治疗特应性皮炎的不同眼部安全性：一项具有眼科和微生物学评估的真实世界研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-05-08 DOI: 10.1080/09546634.2026.2667680

Paulina Stepinska, Kamila Zawadzinska-Halat, Maciej Pastuszczak

{"title":"Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment.","authors":"Paulina Stepinska, Kamila Zawadzinska-Halat, Maciej Pastuszczak","doi":"10.1080/09546634.2026.2667680","DOIUrl":"10.1080/09546634.2026.2667680","url":null,"abstract":"Background: Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.Objectives: To compare ocular outcomes and conjunctival microbiology in patients with moderate-to-severe AD treated with dupilumab versus upadacitinib.Methods: In this prospective real-world study, adult patients were treated with dupilumab or upadacitinib and evaluated at baseline and after 16 weeks. Ocular assessment included the Ocular Surface Disease Index (OSDI) and Schirmer test. Conjunctival swabs were collected for culture. Dermatological outcomes were assessed using EASI and DLQI.Results: Ninety-six patients were included (upadacitinib, n = 52; dupilumab, n = 44). Both treatments significantly improved EASI and DLQI. Conjunctivitis occurred in 39.0% of dupilumab-treated patients and in none of the upadacitinib-treated patients (p < .001). OSDI improved with upadacitinib (-8.3) but worsened with dupilumab (+2.1) (p < .001). Schirmer test results and bacterial colonization did not differ between groups.Conclusions: Dupilumab and upadacitinib showed comparable dermatological efficacy but distinct ocular safety profiles. Dupilumab was associated with more frequent conjunctivitis and worsening ocular symptoms.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2667680"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy of matrix phenolization and nail bed reconstruction for pincer nail deformity: a retrospective study. 基质酚化与甲床重建治疗钳甲畸形的疗效比较：回顾性研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-04-06 DOI: 10.1080/09546634.2026.2646007

Xiang Ji, Xi Yang, Ping Zhu, Zhe-Xi Li, Zi-Chen Zhou, Xin-Fang Li, Aneesha Suddul Ramlochun, Da-Guang Wang

{"title":"Comparative efficacy of matrix phenolization and nail bed reconstruction for pincer nail deformity: a retrospective study.","authors":"Xiang Ji, Xi Yang, Ping Zhu, Zhe-Xi Li, Zi-Chen Zhou, Xin-Fang Li, Aneesha Suddul Ramlochun, Da-Guang Wang","doi":"10.1080/09546634.2026.2646007","DOIUrl":"10.1080/09546634.2026.2646007","url":null,"abstract":"Objective: To compare the efficacy and safety of matrix phenolization and nail bed reconstruction for pincer nail deformity (PND).Methods: This study included 34 patients with 37 nails divided into matrix phenolization group (n = 21) and nail bed reconstruction group (n = 16). The width index, height index, curvature index of nail plate and visual analog scale (VAS) of pain were recorded preoperatively, 6 and 12 months postoperatively. Early postoperative pain, treatment effect, postoperative complications and patient satisfaction were also recorded.Results: The width index was higher, and the height index, curvature index, and VAS were lower at 6 and 12 months after both surgeries (p < 0.05). At 6 months after surgery, the height index and curvature index of nail bed reconstruction were lower than matrix phenolization (p < 0.05). There was no significant difference in the width index and VAS between two groups. At 12 months after surgery, there was no significant difference in the width index, height index, curvature index and VAS between two groups. Two cases had recurrence after matrix phenolization and two cases had nail fold pain after nail bed reconstruction. All patients were satisfied.Conclusion: Matrix phenolization and nail bed reconstruction both showed good efficacy and safety in the treatment of PND. Matrix phenolization has simple operation, mild pain and fast postoperative recovery, which is recommended in clinical practice.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2646007"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147625281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-29 DOI: 10.1080/09546634.2026.2708420

引用次数: 0